Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-ε4/4 genotype

被引:290
作者
Liu, RY
Zhou, JN
van Heerikhuize, J
Hofman, MA
Swaab, DF
机构
[1] Netherlands Inst Brain Res, NL-1105 AZ Amsterdam ZO, Netherlands
[2] Anhui Med Univ, First Affiliated Hosp, Anhui Geriatr Inst, Hefei 230032, Anhui, Peoples R China
关键词
D O I
10.1210/jc.84.1.323
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sleep disruption, nightly restlessness, sundowning, and other circadian disturbances are frequently seen in Alzheimer's disease (AD) patients. Changes in the suprachiasmatic nucleus and pineal gland are thought to be the biological basis for these behavioral disturbances. Melatonin is the main endocrine message for circadian rhythmicity from the pineal. To determine whether melatonin production was affected in AD, melatonin levels were determined in the cerebrospinal fluid (CSF) of 85 patients with AD (mean age, 75 +/- 1.1 yr) and in 82 age-matched controls (mean age, 76 +/- 1.4 yr). Ventricular postmortem CSF was collected from clinically and neuropathologically well defined AD patients and from control subjects without primary neurological or psychiatric disease. In old control subjects (>80 yr of age), CSF melatonin levels were half of those in control subjects of 41-80 yr of age [176 +/- 58 (n = 29) and 350 +/- 66 (n = 53) pg/mL, respectively; P = 0.016]. We did not find a diurnal rhythm in CSF melatonin levels in control subjects. In AD patients the CSF melatonin levels were only one fifth (55 +/- 7 pg/mL) of those in control subjects (273 +/- 47 pg/mL; P = 0.0001). There was no difference in the CSF melatonin levels between the presenile (42 +/- 11 pg/mL; n = 21) and the senile (59 +/- 8 pg/mL; n = 64; P = 0.35) AD patients. The melatonin level in AD patients expressing apolipoprotein E-epsilon 3/4 (71 +/- 11 pg/mL) was significantly higher than that in patients expressing apolipoprotein E-epsilon 4/4 (32 +/- 8 pg/ml; P = 0.02). In the AD patients no significant correlation was observed between age of onset or duration of AD and CSF melatonin levels. In the present study, a dramatic decrease in the CSF melatonin levels was found in old control subjects and even more so in AD patients. Whether supplementation of melatonin may indeed improve behavioral disturbances in AD patients should be investigated.
引用
收藏
页码:323 / 327
页数:5
相关论文
共 53 条
  • [1] [Anonymous], BIOL RHYTHMS CLIN LA
  • [2] Arendt J., 1985, Pineal Research Reviews, V3, P161
  • [3] MELATONIN LEVELS IN HOSPITALIZED ELDERLY PATIENTS - A COMPARISON WITH COMMUNITY BASED VOLUNTEERS
    BASKETT, JJ
    COCKREM, JF
    TODD, MA
    [J]. AGE AND AGEING, 1991, 20 (06) : 430 - 434
  • [4] SEQUENTIAL CEREBROSPINAL-FLUID AND PLASMA SAMPLING IN HUMANS - 24-HOUR MELATONIN MEASUREMENTS IN NORMAL SUBJECTS AND AFTER PERIPHERAL SYMPATHECTOMY
    BRUCE, J
    TAMARKIN, L
    RIEDEL, C
    MARKEY, S
    OLDFIELD, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (04) : 819 - 823
  • [5] IMPAIRED NOCTURNAL SECRETION OF MELATONIN IN CORONARY HEART-DISEASE
    BRUGGER, P
    MARKTL, W
    HEROLD, M
    [J]. LANCET, 1995, 345 (8962) : 1408 - 1408
  • [6] Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186
  • [7] EXPOSURE TO LIGHT IN HEALTHY ELDERLY SUBJECTS AND ALZHEIMERS PATIENTS
    CAMPBELL, SS
    KRIPKE, DF
    GILLIN, JC
    HRUBOVCAK, JC
    [J]. PHYSIOLOGY & BEHAVIOR, 1988, 42 (02) : 141 - 144
  • [8] GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES
    CORDER, EH
    SAUNDERS, AM
    STRITTMATTER, WJ
    SCHMECHEL, DE
    GASKELL, PC
    SMALL, GW
    ROSES, AD
    HAINES, JL
    PERICAKVANCE, MA
    [J]. SCIENCE, 1993, 261 (5123) : 921 - 923
  • [9] NEUROENDOCRINE CORRELATES OF THE AGING BRAIN IN HUMANS
    FERRARI, E
    MAGRI, F
    DORI, D
    MIGLIORATI, G
    NESCIS, T
    MOLLA, G
    FIORAVANTI, M
    SOLERTE, SB
    [J]. NEUROENDOCRINOLOGY, 1995, 61 (04) : 464 - 470
  • [10] Assessment of CSF levels of tan protein in mildly demented patients with Alzheimer's disease
    Galasko, D
    Clark, C
    Chang, L
    Miller, B
    Green, RC
    Motter, R
    Seubert, P
    [J]. NEUROLOGY, 1997, 48 (03) : 632 - 635